[go: up one dir, main page]

MA38642A1 - Compositions pharmaceutiques de composes triazolopyridines substitues pour une utilsation en tant qu'agents anticancereux - Google Patents

Compositions pharmaceutiques de composes triazolopyridines substitues pour une utilsation en tant qu'agents anticancereux

Info

Publication number
MA38642A1
MA38642A1 MA38642A MA38642A MA38642A1 MA 38642 A1 MA38642 A1 MA 38642A1 MA 38642 A MA38642 A MA 38642A MA 38642 A MA38642 A MA 38642A MA 38642 A1 MA38642 A1 MA 38642A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
anticancer agents
triazolopyridine compounds
substituted triazolopyridine
substituted
Prior art date
Application number
MA38642A
Other languages
English (en)
Inventor
Volker Schulze
Michael Brüning
Detlef Stöckigt
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38642(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38642A1 publication Critical patent/MA38642A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques de composés triazolopyridines substitués de la formule générale (i), tels que décrits et définis dans la description, des procédés de préparation desdites compositions et l'utilisation de ces dernières pour le traitement ou la prophylaxie d'une maladie.
MA38642A 2013-06-06 2014-06-05 Compositions pharmaceutiques de composes triazolopyridines substitues pour une utilsation en tant qu'agents anticancereux MA38642A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170754 2013-06-06
PCT/EP2014/061711 WO2014195408A1 (fr) 2013-06-06 2014-06-05 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
MA38642A1 true MA38642A1 (fr) 2017-10-31

Family

ID=48569985

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38642A MA38642A1 (fr) 2013-06-06 2014-06-05 Compositions pharmaceutiques de composes triazolopyridines substitues pour une utilsation en tant qu'agents anticancereux

Country Status (36)

Country Link
US (1) US20160120854A1 (fr)
EP (1) EP3003381B1 (fr)
JP (1) JP2016523229A (fr)
KR (1) KR20160018513A (fr)
CN (1) CN105263526A (fr)
AP (1) AP2015008890A0 (fr)
AR (1) AR096469A1 (fr)
AU (1) AU2014276870A1 (fr)
BR (1) BR112015030292A2 (fr)
CA (1) CA2914439A1 (fr)
CL (1) CL2015003535A1 (fr)
CR (1) CR20150641U (fr)
CU (1) CU24283B1 (fr)
CY (1) CY1119666T1 (fr)
DK (1) DK3003381T3 (fr)
DO (1) DOP2015000295A (fr)
EA (1) EA201501177A1 (fr)
ES (1) ES2652149T3 (fr)
HK (1) HK1219906A1 (fr)
HR (1) HRP20171888T1 (fr)
HU (1) HUE034883T2 (fr)
LT (1) LT3003381T (fr)
MA (1) MA38642A1 (fr)
NI (1) NI201500172A (fr)
NO (1) NO3003381T3 (fr)
PE (1) PE20152028A1 (fr)
PH (1) PH12015502703A1 (fr)
PL (1) PL3003381T3 (fr)
PT (1) PT3003381T (fr)
RS (1) RS56666B1 (fr)
SG (1) SG11201509114TA (fr)
SI (1) SI3003381T1 (fr)
SM (1) SMT201700573T1 (fr)
TN (1) TN2015000524A1 (fr)
UY (1) UY35600A (fr)
WO (1) WO2014195408A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3008062T (lt) * 2013-06-11 2017-06-12 Bayer Pharma Aktiengesellschaft Pakeistųjų triazolpiridinų provaistų dariniai
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
ES2306216T3 (es) * 2004-08-27 2008-11-01 Bayer Pharmaceuticals Corporation Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
CN101125124B (zh) * 2006-08-16 2011-04-20 沈阳药科大学 一种亲脂性药物固体分散体的制备方法
EP2343295A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
EP2343294A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
CN102626384A (zh) * 2012-04-12 2012-08-08 临沂大学 一种姜黄素混悬剂及其制备方法

Also Published As

Publication number Publication date
HUE034883T2 (hu) 2018-03-28
CN105263526A (zh) 2016-01-20
ES2652149T3 (es) 2018-01-31
HRP20171888T1 (hr) 2018-01-12
CU24283B1 (es) 2017-11-07
EP3003381A1 (fr) 2016-04-13
PH12015502703A1 (en) 2016-03-14
HK1219906A1 (zh) 2017-04-21
AR096469A1 (es) 2015-12-30
UY35600A (es) 2015-01-30
SG11201509114TA (en) 2015-12-30
CA2914439A1 (fr) 2014-12-11
NO3003381T3 (fr) 2018-02-10
CY1119666T1 (el) 2018-04-04
PE20152028A1 (es) 2016-02-07
TN2015000524A1 (en) 2017-04-06
AU2014276870A1 (en) 2015-11-19
PL3003381T3 (pl) 2018-02-28
LT3003381T (lt) 2017-12-27
AP2015008890A0 (en) 2015-11-30
PT3003381T (pt) 2017-12-20
RS56666B1 (sr) 2018-03-30
EP3003381B1 (fr) 2017-09-13
BR112015030292A2 (pt) 2017-07-25
EA201501177A1 (ru) 2016-06-30
SMT201700573T1 (it) 2018-01-11
DK3003381T3 (en) 2017-12-11
DOP2015000295A (es) 2016-03-15
CL2015003535A1 (es) 2016-07-08
CU20150170A7 (es) 2016-03-31
JP2016523229A (ja) 2016-08-08
CR20150641U (es) 2016-01-29
US20160120854A1 (en) 2016-05-05
NI201500172A (es) 2016-01-06
KR20160018513A (ko) 2016-02-17
SI3003381T1 (en) 2018-01-31
WO2014195408A1 (fr) 2014-12-11

Similar Documents

Publication Publication Date Title
MA40523B1 (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA34308B1 (fr) Triazolopyridines substituées
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA38358A1 (fr) Formulations de composés organiques
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA38642A1 (fr) Compositions pharmaceutiques de composes triazolopyridines substitues pour une utilsation en tant qu'agents anticancereux
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines